Atrophin-1 antisense oligonucleotide provides robust protection from pathology in a fully humanized DRPLA model.
Saved in:
| Title: | Atrophin-1 antisense oligonucleotide provides robust protection from pathology in a fully humanized DRPLA model. |
|---|---|
| Authors: | Smith VL; Department of Neurology, University of Washington, Seattle, WA 98104, USA., Gidi BZ; Department of Neurology, University of Washington, Seattle, WA 98104, USA., Bragg RM; Department of Neurology, University of Washington, Seattle, WA 98104, USA., Cantle JP; Department of Neurology, University of Washington, Seattle, WA 98104, USA., Ben-Varon A; Department of Psychology, Western Washington University, Bellingham, WA 98225, USA., Noble B; Ionis Pharmaceuticals, Inc., Carlsbad, CA 92010, USA., Prades S; CureDRPLA, 360 Fuman St. Suite 218, Brooklyn, NY 11201, USA.; Ataxia UK, 12 Broadbent Close, London N6 5JW, UK., Compton A; CureDRPLA, 360 Fuman St. Suite 218, Brooklyn, NY 11201, USA.; Ataxia UK, 12 Broadbent Close, London N6 5JW, UK., Greenfield J; CureDRPLA, 360 Fuman St. Suite 218, Brooklyn, NY 11201, USA.; Ataxia UK, 12 Broadbent Close, London N6 5JW, UK., Korecka JA; Division of Movement Disorders and Department of Neurology, Mass General Brigham and Harvard Medical School, Boston, MA 02114, USA., Gemos A; Division of Movement Disorders and Department of Neurology, Mass General Brigham and Harvard Medical School, Boston, MA 02114, USA., Yu T; Division of Genetics and Genomics, Boston Children's Hospital, Boston, MA 02115, USA.; Manton Center for Orphan Disease Research, Boston Children's Hospital, Boston, MA 02115, USA.; Department of Pediatrics, Boston Children's Hospital, Boston, MA 02115, USA.; Program in Medical and Population Genetics, Broad Institute of MIT and Harvard, Cambridge, MA 02139, USA., Khurana V; Division of Movement Disorders and Department of Neurology, Mass General Brigham and Harvard Medical School, Boston, MA 02114, USA.; Broad Institute of Harvard and MIT and Harvard Stem Cell Institute, Cambridge, MA 02139, USA., Kordasiewicz HB; Ionis Pharmaceuticals, Inc., Carlsbad, CA 92010, USA., Zhao HT; Ionis Pharmaceuticals, Inc., Carlsbad, CA 92010, USA., Barker-Haliski M; Department of Pharmaceutics, Center for Epilepsy Drug Discovery (CEDD), University of Washington, Seattle, WA 98195, USA., Child DD; Department of Laboratory Medicine and Pathology, University of Washington, Seattle, WA 98104, USA., Carroll JB; Department of Neurology, University of Washington, Seattle, WA 98104, USA.; CureDRPLA, 360 Fuman St. Suite 218, Brooklyn, NY 11201, USA.; Department of Laboratory Medicine and Pathology, University of Washington, Seattle, WA 98104, USA. |
| Source: | Molecular therapy. Nucleic acids [Mol Ther Nucleic Acids] 2025 Dec 31; Vol. 37 (1), pp. 102815. Date of Electronic Publication: 2025 Dec 31 (Print Publication: 2026). |
| Publication Type: | Journal Article |
| Journal Info: | Publisher: Cell Press Country of Publication: United States NLM ID: 101581621 Publication Model: eCollection Cited Medium: Print ISSN: 2162-2531 (Print) Linking ISSN: 21622531 NLM ISO Abbreviation: Mol Ther Nucleic Acids Subsets: PubMed not MEDLINE |
| Database: | MEDLINE Ultimate |
| FullText | Text: Availability: 0 |
|---|---|
| Header | DbId: mdl DbLabel: MEDLINE Ultimate An: 41624332 AccessLevel: 2 PubType: Academic Journal PubTypeId: academicJournal PreciseRelevancyScore: 0 |
| IllustrationInfo | |
| Items | – Name: Title Label: Title Group: Ti Data: Atrophin-1 antisense oligonucleotide provides robust protection from pathology in a fully humanized DRPLA model. – Name: Author Label: Authors Group: Au Data: <searchLink fieldCode="AU" term="%22Smith+VL%22">Smith VL</searchLink>; Department of Neurology, University of Washington, Seattle, WA 98104, USA.<br /><searchLink fieldCode="AU" term="%22Gidi+BZ%22">Gidi BZ</searchLink>; Department of Neurology, University of Washington, Seattle, WA 98104, USA.<br /><searchLink fieldCode="AU" term="%22Bragg+RM%22">Bragg RM</searchLink>; Department of Neurology, University of Washington, Seattle, WA 98104, USA.<br /><searchLink fieldCode="AU" term="%22Cantle+JP%22">Cantle JP</searchLink>; Department of Neurology, University of Washington, Seattle, WA 98104, USA.<br /><searchLink fieldCode="AU" term="%22Ben-Varon+A%22">Ben-Varon A</searchLink>; Department of Psychology, Western Washington University, Bellingham, WA 98225, USA.<br /><searchLink fieldCode="AU" term="%22Noble+B%22">Noble B</searchLink>; Ionis Pharmaceuticals, Inc., Carlsbad, CA 92010, USA.<br /><searchLink fieldCode="AU" term="%22Prades+S%22">Prades S</searchLink>; CureDRPLA, 360 Fuman St. Suite 218, Brooklyn, NY 11201, USA.; Ataxia UK, 12 Broadbent Close, London N6 5JW, UK.<br /><searchLink fieldCode="AU" term="%22Compton+A%22">Compton A</searchLink>; CureDRPLA, 360 Fuman St. Suite 218, Brooklyn, NY 11201, USA.; Ataxia UK, 12 Broadbent Close, London N6 5JW, UK.<br /><searchLink fieldCode="AU" term="%22Greenfield+J%22">Greenfield J</searchLink>; CureDRPLA, 360 Fuman St. Suite 218, Brooklyn, NY 11201, USA.; Ataxia UK, 12 Broadbent Close, London N6 5JW, UK.<br /><searchLink fieldCode="AU" term="%22Korecka+JA%22">Korecka JA</searchLink>; Division of Movement Disorders and Department of Neurology, Mass General Brigham and Harvard Medical School, Boston, MA 02114, USA.<br /><searchLink fieldCode="AU" term="%22Gemos+A%22">Gemos A</searchLink>; Division of Movement Disorders and Department of Neurology, Mass General Brigham and Harvard Medical School, Boston, MA 02114, USA.<br /><searchLink fieldCode="AU" term="%22Yu+T%22">Yu T</searchLink>; Division of Genetics and Genomics, Boston Children's Hospital, Boston, MA 02115, USA.; Manton Center for Orphan Disease Research, Boston Children's Hospital, Boston, MA 02115, USA.; Department of Pediatrics, Boston Children's Hospital, Boston, MA 02115, USA.; Program in Medical and Population Genetics, Broad Institute of MIT and Harvard, Cambridge, MA 02139, USA.<br /><searchLink fieldCode="AU" term="%22Khurana+V%22">Khurana V</searchLink>; Division of Movement Disorders and Department of Neurology, Mass General Brigham and Harvard Medical School, Boston, MA 02114, USA.; Broad Institute of Harvard and MIT and Harvard Stem Cell Institute, Cambridge, MA 02139, USA.<br /><searchLink fieldCode="AU" term="%22Kordasiewicz+HB%22">Kordasiewicz HB</searchLink>; Ionis Pharmaceuticals, Inc., Carlsbad, CA 92010, USA.<br /><searchLink fieldCode="AU" term="%22Zhao+HT%22">Zhao HT</searchLink>; Ionis Pharmaceuticals, Inc., Carlsbad, CA 92010, USA.<br /><searchLink fieldCode="AU" term="%22Barker-Haliski+M%22">Barker-Haliski M</searchLink>; Department of Pharmaceutics, Center for Epilepsy Drug Discovery (CEDD), University of Washington, Seattle, WA 98195, USA.<br /><searchLink fieldCode="AU" term="%22Child+DD%22">Child DD</searchLink>; Department of Laboratory Medicine and Pathology, University of Washington, Seattle, WA 98104, USA.<br /><searchLink fieldCode="AU" term="%22Carroll+JB%22">Carroll JB</searchLink>; Department of Neurology, University of Washington, Seattle, WA 98104, USA.; CureDRPLA, 360 Fuman St. Suite 218, Brooklyn, NY 11201, USA.; Department of Laboratory Medicine and Pathology, University of Washington, Seattle, WA 98104, USA. – Name: TitleSource Label: Source Group: Src Data: <searchLink fieldCode="JN" term="%22101581621%22">Molecular therapy. Nucleic acids</searchLink> [Mol Ther Nucleic Acids] 2025 Dec 31; Vol. 37 (1), pp. 102815. <i>Date of Electronic Publication: </i>2025 Dec 31 (<i>Print Publication: </i>2026). – Name: TypePub Label: Publication Type Group: TypPub Data: Journal Article – Name: TitleSource Label: Journal Info Group: Src Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Cell+Press%22">Cell Press </searchLink><i>Country of Publication: </i>United States <i>NLM ID: </i>101581621 <i>Publication Model: </i>eCollection <i>Cited Medium: </i>Print <i>ISSN: </i>2162-2531 (Print) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2221622531%22">21622531 </searchLink><i>NLM ISO Abbreviation: </i>Mol Ther Nucleic Acids <i>Subsets: </i>PubMed not MEDLINE |
| PLink | https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=41624332 |
| RecordInfo | BibRecord: BibEntity: Identifiers: – Type: doi Value: 10.1016/j.omtn.2025.102815 Languages: – Code: eng Text: English PhysicalDescription: Pagination: StartPage: 102815 Titles: – TitleFull: Atrophin-1 antisense oligonucleotide provides robust protection from pathology in a fully humanized DRPLA model. Type: main BibRelationships: HasContributorRelationships: – PersonEntity: Name: NameFull: Smith VL – PersonEntity: Name: NameFull: Gidi BZ – PersonEntity: Name: NameFull: Bragg RM – PersonEntity: Name: NameFull: Cantle JP – PersonEntity: Name: NameFull: Ben-Varon A – PersonEntity: Name: NameFull: Noble B – PersonEntity: Name: NameFull: Prades S – PersonEntity: Name: NameFull: Compton A – PersonEntity: Name: NameFull: Greenfield J – PersonEntity: Name: NameFull: Korecka JA – PersonEntity: Name: NameFull: Gemos A – PersonEntity: Name: NameFull: Yu T – PersonEntity: Name: NameFull: Khurana V – PersonEntity: Name: NameFull: Kordasiewicz HB – PersonEntity: Name: NameFull: Zhao HT – PersonEntity: Name: NameFull: Barker-Haliski M – PersonEntity: Name: NameFull: Child DD – PersonEntity: Name: NameFull: Carroll JB IsPartOfRelationships: – BibEntity: Dates: – D: 31 M: 12 Text: 2025 Dec 31 Type: published Y: 2025 Identifiers: – Type: issn-print Value: 2162-2531 Numbering: – Type: volume Value: 37 – Type: issue Value: 1 Titles: – TitleFull: Molecular therapy. Nucleic acids Type: main |
| ResultId | 1 |